SCHEDULE 13G/A: BlackRock Discloses 8.0% Stake in Applied Therapeutics Inc.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 8.0% of Applied Therapeutics Inc.'s common stock as of December 31, 2024.

Summary

• BlackRock, Inc. beneficially owns an aggregate of 9,296,075 shares of Applied Therapeutics Inc. common stock.
• This ownership represents 8.0% of the total outstanding common stock of Applied Therapeutics Inc.
• BlackRock, Inc. holds sole voting power over 9,163,775 shares.
• BlackRock, Inc. holds sole dispositive power over 9,296,075 shares.
• No shared voting or shared dispositive power is reported.
• The filing was made by BlackRock, Inc. as a parent holding company or control person.
• Several BlackRock subsidiaries are identified as entities through which the securities are held, including Aperio Group, LLC, BlackRock Advisors, LLC, BlackRock Asset Management Canada Limited, BlackRock Investment Management (Australia) Limited, BlackRock Fund Advisors, BlackRock Asset Management Ireland Limited, BlackRock Institutional Trust Company, National Association, BlackRock Financial Management, Inc., and BlackRock Investment Management, LLC.
• BlackRock Investment Management, LLC is specifically noted as an entity that beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a factual disclosure of ownership, not a performance report or strategic announcement by the issuer. The presence of a large institutional investor like BlackRock can be seen as a positive signal, but the filing itself does not contain performance-related information.

Positives

• The disclosure of a significant stake by a major institutional investor like BlackRock can be perceived as a vote of confidence in Applied Therapeutics Inc.'s long-term prospects.
• Increased institutional ownership can sometimes lead to greater stock stability and liquidity.

Risks

• The filing itself does not detail risks related to Applied Therapeutics Inc.'s operations or financial health, as it is solely an ownership disclosure.

Management Comments

• BlackRock, Inc. certifies that, to the best of its knowledge and belief, the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing reflects a routine disclosure by BlackRock, one of the world's largest asset managers, regarding its passive investment stake in Applied Therapeutics Inc. Such disclosures are standard practice for institutional investors when their beneficial ownership in a public company crosses certain thresholds, indicating a significant, but non-controlling, investment position within the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may influence investor perception and potentially stock trading activity.
• Management: Awareness of a large institutional holder may influence strategic decisions, though BlackRock's filing indicates a passive investment intent.

Key Dates

Keywords

BlackRock, Applied Therapeutics Inc., Schedule 13G, Institutional Ownership, Common Stock, Beneficial Ownership, Investment Management, SEC Filing, Equity Stake